According to CNBC Article Pfizer to supply up to 40 million doses of Covid vaccine to Covax global immunization program.
Pfizer (NYSE: PFE) will supply up to 40 million doses of its coronavirus vaccine to a global alliance aiming to provide poor nations with coronavirus vaccines, the head of the World Health Organization said Friday.The deal will allow Covax — co-led by the WHO — to begin delivering vaccine doses to participating countries in February, WHO’s Director-General Tedros Adhanom Ghebreyesus said during a press briefing. Tedros added that, pending emergency authorization, the program expects 150 million doses of AstraZeneca’s vaccine to become available for distribution in the first quarter of this year. The Covax program aims to provide 2 billion doses of Covid-19 vaccines to participating countries, which includes low- to middle-income nations, by the end of this year. The Pfizer-BioNTech (NASDAQ:BNTX) vaccine requires two shots spread weeks apart, indicating the agreement would cover just 20 million people.
According to Forbes business the global demand for vaccines is expected to grow to 93 billion by 2026, and a small up and comer Avalon GloboCare (NASDAQ: AVCO) is in the process of developing an intranasal vaccine that can serve as a compliment to what is currently on the market. Avalon uses a proprietary S-Layer “surface layer” technology to develop an intranasal vaccine that attaches to the mucosal membrane CEO Dr. David Jin pointed out. “We see our vaccine candidate as a complement to any injectable vaccines in clinical trials, because it could provide first-line immune protection at the virus’s entrance site”. Adding a coat of an S-layer onto solid surfaces can greatly improve the function of a therapeutic, vaccine, or device. The S-layer allows enhanced efficiency and interaction of targeted proteins and molecules for better function.
Avalon GloboCare is in the process of establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Uwe Sleytr, a member of the Austrian Academy of Sciences. In connection with the new facility, Avalon and BOKU have signed a Memorandum of Understanding (MOU) to jointly apply for a matching research grant from the prestigious Christian Doppler Laboratory Foundation. Avalon also has research being done in MIT (Massachusetts Institute of Technology), the UNRLS (University of Natural Resources and life sciences in Australia), Weill Cornell Medicine in New York City and the Lu Daopei Medical Group in China, which has the country’s top ranked hematology and bone marrow transplant program
In the December 2020 issue of Nature’s Biopharma Dealmakers, Avalon’s President and CEO, David Jin, M.D., Ph.D., highlighted Avalon’s ongoing scientific and clinical developments including a first-in-human trial of a mucosal, intranasal vaccine against SARS-CoV-2 that is planned for early 2021. Dr. Jin also described the company’s innovative, allogeneic mesenchymal stromal cell (MSC) therapy candidate, CB-MSC-1, which possess unique anti-inflammatory and immunomodulatory activities, as well as AVA-001, Avalon’s third-generation CAR T cell therapy that has shown robust activity in patients with relapsed, refractory B cell acute lymphoblastic leukemia in a Phase 1 trial (Avalon feature in Biopharma Dealmakers).
“We are excited and motivated to join forces with the researchers at BOKU to drive innovation. We have already begun a collaboration on the mucosal SARS-CoV-2 vaccine and are moving quickly to establish additional joint research endeavors to bring about innovative technologies and new medicines to patients,” said Dr. Jin.
Avalon GloboCare, is a young, $100 million market cap company that has arguably some of the brightest minds in cell-based technology who have a competitive advantage with their “S-Layer” technology in a vaccine market that is expanding rapidly. This small cap biotechnology company is working towards the goal of changing the way we fight the devastating effects of diseases that relentlessly attack our immune systems by using our own bodies against us. In the first quarter of 2020, Avalon GloboCare successfully completed a phase 1 first-in-human clinical study of AVA-001 in China for the treatment of relapsed refractory B cell acute lymphoblastic leukemia (R/R B-ALL). 90% of R/R B-ALL patients achieved complete remission with one dose and within one month of treatment, and then proceeded to a curative-intent allogeneic bone marrow transplant. With more upcoming catalysts in Q4 2020 and early 2021, it is safe to say that there is a large potential upside in AVCO’s stock that currently trades at only $1.24 The company has been well capitalized to date and has very clean cap table relative to its industry peers making it an attractive investment. The question investors are asking themselves is “how long will Avalon be trading in the one dollar range before it breaks out ?”
Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.